Character | Response | |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Character | Response | |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class | Active | Resistant |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lineage | Physiology | General | Growth Tolerances | Hydrol./digest./degr. |
|
|
Health: Unknown
Source: human faeces (CCUG) and clinical sources (wound, gall, urine - CCUG)
DNA G+C(%): 54.6
|
Low T(℃): 4(+)
Mid T(℃): 40(+)
NaCl >6%: 7(+)
|
|
---|
Monosaccharide O/F | Oligosaccharide O/F | Polysaccharide O/F | Polyol O/F | Other O/F |
|
|
|
|
|
---|
Monosaccharide util/assim | Oligosaccharide util/assim | Other carboh. util/assim | Amino acid util/assim | Organic acid util/assim |
|
|
|
|
|
---|
Enzymes: General | Enzymes: Carbohydrate | Enzymes: Protein | Enzymes: Arylamidases | Enzymes: Esters/fats |
|
|
|
|
|
---|
Fuel | Usable Metabolites | Metabolites Released | Special Products | Compounds Produced |
|
---|
Penicillins & Penems (μg/mL) | Cephalosporins (μg/mL) | Aminoglycosides (μg/mL) | Macrolides (μg/mL) | Quinolones (μg/mL) |
aztreonam: S(MIC50): 0.12, MIC90: 0.5, RNG: (≤0.12->16)
piper-taz: Var(MIC50): 2, MIC90: 32, RNG: (≤0.5-256)
imipenem: S(MIC50): 0.5, MIC90: 1, RNG: (≤0.12-2)
|
cefepime: S(MIC50): 0.12, MIC90: 0.25, RNG: (≤0.12->16)
ceftazidime: Var(MIC50): 0.5, MIC90: 8, RNG: (0.25->8)
|
amikacin: S(MIC50): 2, MIC90: 4, RNG: (≤0.25->32)
gentamicin: Var(MIC50): >2, MIC90: >8, RNG: (≤2->8)
|
|
ciprofloxacin: S(MIC50): 0.06, MIC90: 1, RNG: (≤0.03->4)
gatifloxacin: S(MIC50): 0.25, MIC90: 2, RNG: (≤0.03->4)
trovafloxacin: S(MIC50): 0.015, MIC90: 0.03, RNG: (≤0.015-0.03)
|
---|---|---|---|---|
Tetracyclines (μg/mL) | Vancomycin Class (μg/mL) | Polypep/ketides (μg/mL) | Heterocycles (μg/mL) | Other (μg/mL) |
minocycline: S(MIC50): 2, MIC90: 4, RNG: (0.5->8)
tetracycline: Var(MIC50): >8, MIC90: >8, RNG: (≤2->8)
tigecycline: S(MIC50): 1, MIC90: 1, RNG: (0.25-8)
|
|
|
co-trimoxazole: S(MIC50): ≥0.5, MIC90: ≥2, RNG: (≤0.5->2)
|
|